Blood Res.  2024;59:25. 10.1007/s44313-024-00029-3.

Proper application of anticoagulation therapy on cancer‑associated venous thrombosis

• Yhim H

• KMID: 2562529
• DOI: http://doi.org/10.1007/s44313-024-00029-3

Abstract

Cancer-associated venous thromboembolism (VTE) significantly impacts morbidity and mortality. The introduction of direct oral anticoagulants over the past decade has revolutionized VTE treatment in patients with active cancer, offering potential advantages over traditional therapies. However, uncertainties persist regarding the optimal selec‑ tion and dosage of anticoagulants, particularly in patients with specific risk factors for bleeding, such as certain cancer types (e.g., upper gastrointestinal cancer, genitourinary cancer, primary or metastatic brain tumor, and hematologic malignancies) and specific patient characteristics (e.g., renal dysfunction and thrombocytopenia). Recent data on the thrombotic risk associated with low thrombotic burden VTE, such as subsegmental pulmonary embolism and isolated distal deep vein thrombosis, underscore the need for updated management strategies in daily clini‑ cal practice. This review aims to explore these issues and highlight the evolving landscape of cancer-associated VTE management.

Keyword

Anticoagulation; Cancer; Venous thromboembolism

Reference

1. Khorana AA. 2010; Venous thromboembolism and prognosis in cancer. Thromb Res. 125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023. PMID: 20097409. PMCID: PMC2878879.

2. Carrier M, Prandoni P. 2017; Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol. 10(1):15–22. DOI: 10.1080/17474086.2017.1257935. PMID: 27869512.

3. Yhim HY. 2022; Challenging issues in the management of cancer-associated venous thromboembolism. Blood Res. 57(S1):44–8. DOI: 10.5045/br.2022.2022025. PMID: 35483925. PMCID: PMC9057672.

4. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. 2002; Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 162(11):1245–8. DOI: 10.1001/archinte.162.11.1245. PMID: 12038942.

5. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. 2007; Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 5(3):632–4. DOI: 10.1111/j.1538-7836.2007.02374.x. PMID: 17319909.

6. Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. 2004; Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 164(15):1653–61. DOI: 10.1001/archinte.164.15.1653. PMID: 15302635.

7. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000; Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 343(25):1846–50. DOI: 10.1056/NEJM200012213432504. PMID: 11117976.

8. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. 2018; Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 378(7):615–24. DOI: 10.1056/NEJMoa1711948. PMID: 29231094.

9. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. 2018; Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 36(20):2017–23. DOI: 10.1200/JCO.2018.78.8034. PMID: 29746227.

10. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. 2020; Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 18(2):411–21. DOI: 10.1111/jth.14662. PMID: 31630479.

11. Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM, et al. 2020; Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 382(17):1599–607. DOI: 10.1056/NEJMoa1915103. PMID: 32223112.

12. Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahe I, et al. 2022; Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 161(3):781–90. DOI: 10.1016/j.chest.2021.09.037. PMID: 34627853.

13. Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. 2023; Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 329(22):1924–33. DOI: 10.1001/jama.2023.7843. PMID: 37266947. PMCID: PMC10265290.

14. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. 2023; Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 41(16):3063–71. DOI: 10.1200/JCO.23.00294. PMID: 37075273.

15. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. 2021; American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 5(4):927–74. DOI: 10.1182/bloodadvances.2020003442. PMID: 33570602. PMCID: PMC7903232.

16. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. 2021; Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 160(6):e545–608. DOI: 10.1016/j.chest.2021.07.055. PMID: 34352278.

17. Konstantinides SV, Meyer G. 2019; The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 40(42):3453–5. DOI: 10.1093/eurheartj/ehz726. PMID: 31697840.

18. Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, et al. 2018; Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 16(9):1891–4. DOI: 10.1111/jth.14219. PMID: 30027649.

19. Almarshad F, Alaklabi A, Raizah AA, AlZahrani Y, Aljohani SA, AlShammari RK, et al. 2023; Diagnostic approach and use of CTPA in patients with suspected pulmonary embolism in an emergency department in Saudi Arabia. Blood Res. 58(1):51–60. DOI: 10.5045/br.2023.2023007. PMID: 36922446. PMCID: PMC10063597.

20. Font C, Farrus B, Vidal L, Caralt TM, Visa L, Mellado B, et al. 2011; Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol. 22(9):2101–6. DOI: 10.1093/annonc/mdq720. PMID: 21325446.

21. Yhim HY, Choi WI, Kim SH, Nam SH, Kim KH, Mun YC, et al. 2019; Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. Korean J Intern Med. 34(5):1125–35. DOI: 10.3904/kjim.2018.097. PMID: 29788694. PMCID: PMC6718768. PMID: 3db44610c67e49fa933bfb46c7c3a54b.

22. Cho H, Choi JH, Kang SY, Lee HW, Choi YW, Kim TH, et al. 2022; Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin. Korean J Intern Med. 37(3):653–9. DOI: 10.3904/kjim.2021.309. PMID: 35439872. PMCID: PMC9082433. PMID: ecaca389f3d04368b9914e17fec0868d.

23. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. 2011; Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 29(17):2405–9. DOI: 10.1200/JCO.2010.34.0984. PMID: 21555690.

24. Donato AA, Khoche S, Santora J, Wagner B. 2010; Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography. Thromb Res. 126(4):e266–270. DOI: 10.1016/j.thromres.2010.07.001. PMID: 20709366.

25. Hong J, Ahn SY, Lee YJ, Lee JH, Han JW, Kim KH, et al. 2021; Updated recommendations for the treatment of venous thromboembolism. Blood Res. 56(1):6–16. DOI: 10.5045/br.2021.2020083. PMID: 33627521. PMCID: PMC7987480.

26. Di Nisio M, Lee AY, Carrier M, Liebman HA, Khorana AA, et al. Subcommittee on H. 2015; Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 13(5):880–3. DOI: 10.1111/jth.12883. PMID: 25714858.

27. van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, et al. 2016; Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 14(1):105–13. DOI: 10.1111/jth.13172. PMID: 26469193. PMCID: PMC7480998.

28. Kraaijpoel N, Bleker SM, Meyer G, Mahe I, Munoz A, Bertoletti L, et al. 2019; Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study. J Clin Oncol. 37(20):1713–20. DOI: 10.1200/JCO.18.01977. PMID: 31116676.

29. Galanaud JP, Trujillo-Santos J, Bikdeli B, Bertoletti L, Di Micco P, Poenou G, et al. 2024; Clinical presentation and outcomes of patients with cancer-associated isolated distal deep vein thrombosis. J Clin Oncol. 42(5):529–37. DOI: 10.1200/JCO.23.00429. PMID: 37471683.

30. Frere C, Farge D, Schrag D, Prata PH, Connors JM. 2022; Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancerassociated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 15(1):69. DOI: 10.1186/s13045-022-01289-1. PMID: 35598026. PMCID: PMC9124390. PMID: e0495a793fc240d193fbf6308c0c5791.

31. Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, et al. 2018; Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost. 118(8):1439–49. DOI: 10.1055/s-0038-1667001. PMID: 30060256.

32. Lee JY, Oh IY, Lee JH, Kim SY, Kwon SS, Yang HJ, et al. 2020; The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants. Thromb Res. 195:243–9. DOI: 10.1016/j.thromres.2020.07.054. PMID: 32823239.

33. Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, et al. 2020; Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med. 180(8):1052–60. DOI: 10.1001/jamainternmed.2020.1835. PMID: 32511684. PMCID: PMC7281381.

34. Yoon SY, Won JH. 2023; Novel therapeutic strategies for essential thrombocythemia/polycythemia vera. Blood Res. 58(S1):83–9. DOI: 10.5045/br.2023.2023013.

35. Fredenburgh JC, Weitz JI. 2021; Factor XI as a target for new anticoagulants. Hamostaseologie. 41(2):104–10. DOI: 10.1055/a-1384-3715. PMID: 33860518.

36. Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. 2021; Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol. 78(6):625–31. DOI: 10.1016/j.jacc.2021.06.010. PMID: 34353538. PMCID: PMC8552338.

37. Wang TF, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, Buller HR, et al. 2023; Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction. Oncologist. 28(7):555–64. DOI: 10.1093/oncolo/oyad116. PMID: 37171998. PMCID: PMC10322141.

38. Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, et al. 2022; Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 20(2):307–15. DOI: 10.1111/jth.15577. PMID: 34714969. PMCID: PMC9298689.

39. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. 2015; Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 13(6):1028–35. DOI: 10.1111/jth.12923. PMID: 25827941.

40. McBane R, Loprinzi C, Zemla T, Tafur A, Sanfilippo K, Liu J, et al. 2024; J Thromb Haemost. 22(6):1704–14. https://doi.org/10.1016/j.jtha.2024.03.011. DOI: 10.1016/j.jtha.2024.03.011. PMID: 38537780.